Related Experiment Video

Updated: Aug 9, 2026

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study

Dirk J van Veldhuisen1, Halfdan Aass, Dia El Allaf

  • 1Department of Cardiology, Thoraxcenter, University Medical Center Groningen, PO Box 30 001, 9700 RB Groningen, The Netherlands. d.j.van.veldhuisen@thorax.umcg.nl

European Journal of Heart Failure
|March 29, 2006
PubMed

Insights

Beta-blocker therapy with metoprolol CR/XL significantly reduced new atrial fibrillation in heart failure patients with sinus rhythm. However, its effect on mortality in patients with existing atrial fibrillation remains unclear.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation is a prevalent comorbidity in heart failure patients.
  • Limited data exists on the efficacy of beta-blockers in preventing new-onset atrial fibrillation in this population.

Purpose of the Study:

  • To investigate the impact of metoprolol CR/XL on atrial fibrillation incidence and mortality in patients with heart failure.

Main Methods:

  • Analysis of baseline electrocardiograms (ECGs) for rhythm in the MERIT-HF trial.
  • Assessment of atrial fibrillation occurrence during follow-up.
  • Comparison of outcomes between metoprolol CR/XL and placebo groups.

Main Results:

  • Metoprolol CR/XL demonstrated a significant reduction in new-onset atrial fibrillation (RR 0.53; p=0.0005).
  • No significant effect of metoprolol CR/XL on mortality was observed in patients with baseline atrial fibrillation.
  • Similar heart rate reduction and drug dosages were noted between patients with atrial fibrillation and sinus rhythm.

Conclusions:

  • Metoprolol CR/XL effectively reduces the incidence of new atrial fibrillation in heart failure patients initially in sinus rhythm.
  • The study could not establish a clear interaction between metoprolol and mortality in patients with co-existing atrial fibrillation and heart failure.
  • Caution is advised when interpreting subgroup analyses regarding metoprolol's effects.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...